1332 — Touyun Biotech Income Statement
0.000.00%
Last trade - 00:00
- HK$561.19m
- HK$931.98m
- HK$198.64m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 343 | 207 | 284 | 316 | 199 |
Cost of Revenue | |||||
Gross Profit | 125 | 84.6 | 107 | 120 | 56.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 572 | 322 | 389 | 493 | 464 |
Operating Profit | -229 | -116 | -106 | -178 | -265 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -195 | -172 | -123 | -199 | -273 |
Provision for Income Taxes | |||||
Net Income After Taxes | -199 | -172 | -124 | -203 | -273 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -201 | -169 | -72.9 | -198 | -269 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -201 | -169 | -72.9 | -198 | -269 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.037 | -0.061 | -0.021 | -0.07 | -0.077 |